



Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference

August 6, 2024

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- [Generation Bio Co.](#) (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th, 2024 at 2:30 p.m. ET in Boston.

A live webcast of the presentation will be available on the investor section of the company's website at [investors.generationbio.com](#). A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.

For more information, please visit [www.generationbio.com](#).

Investors and Media Contact

Maren Killackey

Generation Bio

mkillackey@generationbio.com

857-371-4638